Abstracts tagged "SLE"

Abstract Number: 2091 • 2018 ACR/ARHP Annual Meeting
Mucosal-Associated Invariant T (MAIT) Cells As a Potential Therapeutic Target for Systemic Lupus Erythematosus
Goh Murayama¹, Asako Chiba², Atsushi Nomura³, Hirofumi Amano¹, Ken Yamaji¹, Naoto Tamura¹ and Sachiko Miyake^4,5, ¹Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Juntendo Univ Sch of Med, Juntendo University School of Medicine, Tokyo, Japan, ³JUNTENDO UNIVERSITY SCHOOL OF MEDICINE, Tokyo, Japan, ⁴Division of Immunology/NCNP, Natl Institute of Neuroscience, Kodaira Tokyo, Japan, ⁵Immunology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate T cells that are restricted by the nonpolymorphic MHC-related molecule-1 (MR1) and express a semi-invariant TCRα chain:…
Abstract Number: 2436 • 2018 ACR/ARHP Annual Meeting
The Impact of Different Classes of Lupus Nephritis on Maternal and Fetal Outcomes
Bruna Costa Rodrigues¹, Marcela Ignacchiti Lacerda¹, Guilherme Ramires de Jesus², Flavia Cunha dos Santos², Nilson Ramires de Jesus², Roger Abramino Levy^1,3 and Evandro Mendes Klumb¹, ¹Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Immunology and Inflammation, GlaxoSmithKline, Upper Providence, PA
Background/Purpose: During pregnancy, history of lupus nephritis (LN) has been independently associated with increased risk of adverse maternal and fetal outcomes, which are even more…
Abstract Number: 104 • 2018 ACR/ARHP Annual Meeting
Identification of a Gut Pathobiont Immunostimulatory Lipoglycan Antigen Linked to Lupus Nephritis
Gregg Silverman¹, Nicolas Gisch², Aidana Omarbekova³ and Doua F. Azzouz⁴, ¹Department of Medicine, New York University School of Medicine, New York, NY, ²Research Center Borstel, Schleswig-Holstein, Germany, ³New York University School of Medicine, New York, NY, ⁴Medicine, New York University School of Medicine, New York, NY
Background/Purpose: A transmissible agent has long been suspected in SLE. In a discovery cohort we found that,compared with healthy subjects, Lupus patients had a five-fold…
Abstract Number: 759 • 2018 ACR/ARHP Annual Meeting
Comparison of Length of Stay and Total Hospital Charges for Hospitalizations for Sepsis in Patients with Systemic Lupus Erythematosus: A Study of National Inpatient Sample Database 2010 to 2014
Karan Chugh¹, Shraddha Jatwani², Karan Jatwani³ and Jasleen Kaur⁴, ¹Division of Pulmonary, Critical Care & Sleep, Wayne State University/Detroit Medical Center, Detroit, MI, ²Department of Internal Medicine, Division of Rheumatology, Henry Ford Allegiance Health, Jackson, MI, ³Department of Internal Medicine, Mount Sinai West - St Luke’s Hospital, New York, NY, ⁴Department of Internal Medicine, Wayne State University/Detroit Medical Center, Detroit, MI
Background/Purpose: Sepsis is a systemic inflammatory response syndrome caused by an infection with at least one acute organ failure and is major public health concern.1…
Abstract Number: 1388 • 2018 ACR/ARHP Annual Meeting
Characteristics and Symptom Severity in 21,101 Patients Reporting Systemic Lupus Erythematous in the Patientslikeme Online Health Community
Elisabeth Nyman¹, Edward R. Hammond², Timothy Vaughan³, Barnabas Desta², Xia Wang², Volkan Barut⁴ and Cathy Emmas⁵, ¹Advanced Analytics Centre, AstraZeneca, Gothenburg, Sweden, ²AstraZeneca, Gaithersburg, MD, ³PatientsLikeMe, Boston, MA, ⁴Global Medical Affairs, AstraZeneca, Cambridge, United Kingdom, ⁵Patient Centricity, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: Online health communities and research networks such as PatientsLikeMe (PLM) provide important insight into understanding chronic diseases, including systemic lupus erythematous (SLE). We aimed…
Abstract Number: 2092 • 2018 ACR/ARHP Annual Meeting
Glucocorticoid-Induced Leucine Zipper (GILZ) Is a Novel Checkpoint Regulator of Type I Interferon (IFN) Production in SLE
Champa Nataraja¹, Eric Morand¹, Jacinta Lee¹, Taylah Bennett¹, Jacqueline Flynn¹, James Harris¹ and Sarah Jones², ¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ²School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: Glucocorticoids (GC) remain the frontline treatment in Systemic Lupus Erythematosus (SLE) despite their predictable metabolic adverse effects. Type I interferons (IFN), produced by TLR7…
Abstract Number: 2441 • 2018 ACR/ARHP Annual Meeting
Needs and Barriers to Pregnancy Counselling in Women with SLE
Autumn Neville¹, Natalie Dayan¹, Cheryl Barnabe², Susan Elliott³, Laurie Proulx⁴, Deborah Da Costa⁵, Sasha Bernatsky⁶ and Evelyne Vinet⁷, ¹McGill University Health Centre, Montreal, QC, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³GEOGRAPHY AND ENVIRONMENTAL MANAGEMENT, University of Waterloo, Waterloo, ON, Canada, ⁴Canadian Arthritis Patient Alliance, Ottawa, ON, Canada, ⁵Medicine, McGill University, Montreal, QC, Canada, ⁶Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁷Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Existing data suggest that barriers to pregnancy counselling exist and might represent an area of need in order to optimize outcomes for SLE pregnancies.…
Abstract Number: 107 • 2018 ACR/ARHP Annual Meeting
Apolipoprotein L1 Risk Variants, Renal Histopathology, and Prognosis in African American SLE Nephritis Patients: A Cohort Study
Ashira Blazer¹, Ming Wu², Nancyanne Schmidt³, Alana Engelbrecht⁴, Feng-Xia Liang⁵, Robert M. Clancy⁶, Jill P. Buyon⁷ and H. Michael Belmont⁸, ¹Internal Medicine Division of Rheumatology, NYU School of Medicine, New York, NY, ²Department of Pathology, New York University, New York, NY, ³Internal Medicine, New York University School of Medicine, New York, NY, ⁴Rheumatology, NYU Langone Health, New York, NY, ⁵Office of Science and Research, New York University School of Medicine, New York, NY, ⁶Colton Center for Autoimmunity, New York University, New York, NY, ⁷Rheumatology, NYU School of Medicine, New York, NY, ⁸Division of Rheumatology, New York University, New York, NY
Background/Purpose: Apolipoprotein L1 (APOL1) risk variants (RV), G1 and G2, associate with CKD in African Americans (AA) and are evolutionarily preserved due to improved infectious…
Abstract Number: 773 • 2018 ACR/ARHP Annual Meeting
Exploring the Relation between Immunoglobulins Level and Infection Risk in Adult Patients with Systemic Lupus Erythematosus
Ibrahim Almaghlouth^1,2, Jiandong Su³, Eleanor Pullenayegum⁴, Sindhu Johnson⁵, Dafna D Gladman³ and Murray Urowitz⁶, ¹Division of Rheumatology, Department of medicine, King Saud University, King Khalid University Hospital, Riyadh, Saudi Arabia, ²Division of Rheumatology, Department of medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, ⁵Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ⁶Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Infection is a major cause of mortality in all stages of disease in systemic lupus erythematosus (SLE). Several risk factors for infection have been…
Abstract Number: 1389 • 2018 ACR/ARHP Annual Meeting
Depression and the Patient Reported Outcomes Measurement Information System in Systemic Lupus Erythematosus
Brett Dietz¹, Patricia Katz¹, Maria Dall'Era², Louise Murphy³, Cristina Lanata¹, Laura Trupin¹ and Jinoos Yazdany², ¹University of California San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Health-related quality of life (HRQoL) is reduced in SLE. Depression is a possible contributor to reduced HRQoL. The relationship between major depression and HRQoL…
Abstract Number: 2093 • 2018 ACR/ARHP Annual Meeting
Glucocorticoid-Induced Leucine Zipper (GILZ) Deficiency Worsens Autoimmunity in the Lyn-Deficient Murine Model of Lupus By Disinhibiting the Type I Interferon (IFN) Pathway
Champa Nataraja¹, Eric Morand¹, Jacinta Lee¹, Taylah Bennett¹, Jacqueline Flynn¹, James Harris¹ and Sarah Jones², ¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ²School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease associated with B cell hyperactivity driven by dysregulated type I IFN. Lyn-deficient mice develop lupus-like…
Abstract Number: 2630 • 2018 ACR/ARHP Annual Meeting
Complement C4d Split Products in Combination with Lupus Anticoagulant and Low Complement Associate with Thrombosis in Systemic Lupus Erythematosus
Michelle Petri¹, John Conklin², Robert Apilado², Tyler O'Malley², JoAnne Ligayon², Leilani Wolover² and Thierry Dervieux², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: Lupus anticoagulant (LAC) is an established risk factor for thrombosis in systemic Lupus erythematosus (SLE). Emerging data suggest that activation of the complement system…
Abstract Number: 9L • 2017 ACR/ARHP Annual Meeting
Circulating Type I, II and III Interferons (IFNs) Associate with IFN-Scores, but Define Distinct Subsets of Active SLE
Vilija Oke¹, Iva Gunnarsson¹, Jessica M. Dorschner², Agneta Zickert¹, Timothy B. Niewold³ and Elisabet Svenungsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Colton Center for Autoimmunity, New York University, New York, NY

Background/Purpose: Serum induced IFN gene expression (IFN-score) is considered a golden standard to assess IFN activity in SLE. So far, IFN-scores have not been compared…
Abstract Number: 177 • 2017 ACR/ARHP Annual Meeting
Intronic Variants of the B-Cell Proliferator RASGRP3 Affect Its Expression, and Might Contribute to Lupus Risk
Bhupinder Singh¹, Philip Borden², Julio Molineros³, Celi Sun³, Loren Looger² and Swapan Nath¹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, OKlahoma City, OK, ²Howard Hughes Medical Institute, Ashburn, VA, ³Oklahoma Medical Research Foundation, OKlahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease with complex genetic underpinnings. Variants from RASGRP3 (RAS Guanyl Releasing Protein 3) is one of…
Abstract Number: 986 • 2017 ACR/ARHP Annual Meeting
Do Death Certificates Underestimate the Burden of Rare Diseases: The Example of Systemic Lupus Erythematosus Mortality in Sweden
Titilola Falasinnu¹, Marios Rossides², Yashaar Chaichian³ and Julia F Simard⁴, ¹Health Research and Policy, Stanford University, Stanford, CA, ²Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ³Medicine, Immunology & Rheumatology Division, Stanford School of Medicine, Stanford, CA, ⁴Division of Epidemiology, Health Research and Policy Department, Stanford School of Medicine, Stanford, CA
Background/Purpose: Routine data sources such as death certificates are used to estimate the burden or cost of disease in a population. However, mortality due to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].